Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
about
Non-centrosomal TPX2-Dependent Regulation of the Aurora A Kinase: Functional Implications for Healthy and Pathological Cell DivisionAurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationAurora kinases: novel therapy targets in cancersGrowth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis?TPX2 expression is associated with poor survival in gastric cancer.The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences.Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.Protein Kinase Targets in Breast Cancer.Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.
P2860
Q26752389-45C9C744-196F-431D-87CF-6AD6AE94E759Q33566511-78530597-107D-4EC5-838F-0412D12C1CAEQ33618929-784271A4-E09C-4C70-9198-2F755195F986Q36240957-F23803A1-A2EA-417E-BC28-D936D7C2EDBBQ37576195-F7C2B43D-3529-4B94-AB22-C613F23CB0DCQ37709004-17C47B6D-1B3B-4E0B-AE4C-62597F87C7F2Q38930155-C3EE4A12-7F58-4AD6-983A-58D62A4EBBB5Q38940139-78751AFC-791F-47CB-9D3B-CCE14DED0B1AQ47156672-FA35E830-9DC9-4D17-9DCB-4CCD377E592CQ47161308-49D5E790-7C7B-4195-A872-0C914CCBB6E8Q47351355-5706A4EB-346A-4C23-94E7-BCB1E9FC1214Q48157676-A365C8DD-2878-4AF4-940B-15E7F3572743Q52657032-FD1CAB71-EBAD-41CC-B116-51E4EFB7066B
P2860
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@ast
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@en
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@nl
type
label
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@ast
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@en
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@nl
prefLabel
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@ast
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@en
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@nl
P2093
P2860
P3181
P356
P1476
Scientific Rationale Supportin ...... Inhibitor Alisertib in Cancer
@en
P2093
Huifeng Niu
Jeffrey A Ecsedy
Mark Manfredi
P2860
P3181
P356
10.3389/FONC.2015.00189
P407
P577
2015-01-01T00:00:00Z